Claire Friedman, MD
Internal Medicine · New York, NYNPI 1972897585
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Eli Lilly at 28.0% of the total. Reporting peaked in 2022 at $3,826 and has fallen 58.2% since, to $1,600 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 16 payments — averaging $714.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- Aadi Bioscience, Inc.$2K
- Puma Biotechnology, Inc.$2K
- Seagen Inc.$1K
- GSK$1K
- E.r. Squibb & Sons, L.L.C.$799
- plus $982 from 3 others
Across 168 payments — averaging $28,643 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$1.6M
- Genentech, Inc.$1.4M
- E.r. Squibb & Sons, L.L.C.$653K
- AstraZeneca$315K
- Eli Lilly$211K
- Daiichi Sankyo Company LTD$147K
- plus $402K from 6 others
What the payments were for
- Consulting fees$6,52557%
- Speaking & faculty fees$2,20019%
- Travel & lodging$1,52613%
- Food & beverage$6496%
- Charitable contribution$5315%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $3,200 |
| Aadi Bioscience, Inc. | 2 | $2,250 |
| Puma Biotechnology, Inc. | 1 | $1,526 |
| Seagen Inc. | 2 | $1,375 |
| GSK | 1 | $1,300 |
| E.r. Squibb & Sons, L.L.C. | 2 | $799 |
| AstraZeneca | 3 | $639 |
| Merck | 2 | $196 |
| AbbVie | 1 | $147 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,431 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 20 | $479,919 |
| LynparzaOlaparib | 35 | $366,519 |
| ZejulaNiraparib Tosylate | 14 | $236,282 |
| Prednisolone Acetate | 19 | $924 |
| Letrozole | 26 | $545 |
| Ondansetron Hcl | 47 | $403 |
| Dexamethasone | 19 | $272 |
| Levothyroxine Sodium | 20 | $225 |
| Gabapentin | 35 | $210 |
| Olanzapine | 14 | $198 |
| Amlodipine Besylate | 43 | $194 |
| Pantoprazole Sodium | 37 | $164 |
| Losartan Potassium | 28 | $160 |
| Tramadol Hcl | 15 | $87 |
| Omeprazole | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $639 | $366,51935 claims |
| GSKZejula | $1,300 | $236,28214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
- Terry PlasseNew York$883K
- Krisczar BungayNew York$554K
- Eytan SteinNew York$496K
- Larry NeumanNew York$457K
- Wuhua JingNew York$338K
- Harvey SchneienNew York$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.